Login / Signup

Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry.

Andrea ChiricozziMarina TalamontiClara De SimoneMarco GalluzzoNiccolò GoriGabriella FabbrociniAngelo Valerio MarzanoGiampiero GirolomoniAnnamaria OffidaniMaria Teresa RossiLuca BianchiAntonio CristaudoMaria Teresa FierroLuca StingeniGiovanni PellacaniGiuseppe ArgenzianoAnnalisa PatriziPaolo PigattoMarco RomanelliPaola SavoiaPietro RubegniCaterina FotiNicola MilanesiAnna Belloni FortinaMaria Rita BongiornoTeresa GriecoSergio Di NuzzoMaria Concetta FargnoliAndrea CarugnoAlberico MotoleseFranco RongiolettiPaolo AmerioRiccardo BalestriConcetta PotenzaGiuseppe MicaliCataldo PatrunoIris ZalaudekMaurizio LombardoClaudio FelicianiLucia Di NardoFabrizio GuarneriKetty Perisnull null
Published in: Allergy (2021)
Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • atopic dermatitis
  • ejection fraction
  • prognostic factors
  • coronavirus disease
  • sars cov
  • peritoneal dialysis
  • patient reported outcomes
  • drug induced